Antares Pharma (AIS) Reports a Q3 Loss In-line W/Estimates
AIS Hot Sheet
Revenue Growth %: +63.6%Financial Fact:
Product sales: 2.49M
Today's EPS Names:
SAPX, ECTY, TRNS, More
Antares Pharma, Inc. (NYSE: AIS) reports a Q3 loss of $0.04, in-line with the analyst estimate of ($0.04). Revenue for the quarter was $2.0 million, which compares to the estimate of $1.89 million.
You May Also Be Interested In
- UPDATE: Lowe's (LOW) Beats Q1 Views Amid Lagging Seasonal Demand; Issues Light FY12 Earnings Outlook
- Transcat, Inc. (TRNS) Posts Stronger Q4 EPS of 14c
- Urban Outfitters (URBN) Shares Up 6+% Following Strong Q1 Earnings
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
